| Literature DB >> 32771062 |
Christiane Pereira Martins Casteli1,2, Gisèle Irène Claudine Mbemba1, Serge Dumont3,4, Clémence Dallaire1,5, Lucille Juneau2,6, Elisabeth Martin1,4, Marie-Claude Laferrière7, Marie-Pierre Gagnon8,9.
Abstract
BACKGROUND: Home-based hospitalization (HBH) offers an alternative delivery model to hospital care. There has been a remarkable increase in pilot initiatives and deployment of this model to optimize services offered to a population with a variety of progressive and chronic diseases. Our objectives were to systematically summarize the indicators of HBH as well as the factors associated with the successful implementation and use of this model.Entities:
Keywords: Home care; Home hospital; Home-based hospitalization; Meta-analysis; Systematic review
Mesh:
Year: 2020 PMID: 32771062 PMCID: PMC7415182 DOI: 10.1186/s13643-020-01423-5
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Definition of PICOS criteria for the eligibility of studies
| Patients with chronic diseases, acute conditions, or in palliative care | |
| Home-based hospitalization (HBH) | |
| Conventional hospital care | |
| Systematic review of quantitative, qualitative, or mixed-methods studies, with or without meta-analysis |
Fig. 1PRISMA study flow diagram
Summary of characteristics of included studies
| Author, year, country | Type of reviews or designs | Population | Intervention | Outcomes | AMSTAR |
|---|---|---|---|---|---|
Systematic review Mixed | Adult patients | Parenteral cancer drug administration | Quality of life, patient’s satisfaction, safety, and costs | Moderate | |
Systematic review Qualitative | Not specified | Interventions supporting continuity of care, including HBH | Number of readmissions, mortality, or improvement in functional capacity | Moderate | |
Systematic review and meta-analysis Quantitative | Patients aged 18 years and over | Early discharge hospital at home | Effectiveness and cost of the intervention | High | |
Systematic review Qualitative | Patients aged over 65 years | Any community-based intervention offered as an alternative to admission to an acute hospital | Reduction in secondary care use, patient-related outcomes, safety, and costs | Moderate | |
Systematic review and meta-analysis Quantitative | People aged 18 years and older | Home-based end-of-life care | Place of death, admission to hospital, patient satisfaction, caregiver burden, health service costs. | High | |
Systematic review and meta-analysis Quantitative | Patients aged 18 years and over. | Hospital at home | Mortality, transfer to hospital, place of residence, length of stay, patient satisfaction, cost | High | |
Systematic review and meta-analysis Quantitative | Patients with acute exacerbation of chronic obstructive pulmonary disease | Early supported discharge (ESD) and hospital at home (HAH) | Readmissions, mortality, and cost. | Moderate | |
Systematic review and meta-analysis Quantitative | Patients who required hospitalization for decompensated heart failure | Substitutive care models | Mortality, hospital readmissions, other clinical, patient-centered, and cost outcomes | High | |
Systematic review and meta-analysis Quantitative | Patients aged > 16 years | Hospital at home care models | Mortality, readmission rates, patient and carer satisfaction, and costs | Moderate | |
Systematic review and meta-analysis Quantitative | Patients with a diagnosis of COPD with an acute exacerbation | Hospital at home care | Readmission rate, mortality, costs, and days of care provision | High | |
Systematic review Quantitative | Children and adolescents aged 0–18 years with a cancer diagnosis | Care in the patient’s own home as an alternative to a hospital admission | Children’s physical health and adverse events, satisfaction and quality of life of children and their parents, and costs | Low | |
Systematic review and meta-analysis Quantitative | Patients aged 18 years and over | Early discharge hospital at home | Mortality, readmissions, patient satisfaction, length of stay in hospital and hospital at home, cost | Moderate | |
Systematic review and meta-analysis Quantitative | Patients aged 18 years and older | Hospital care at home | Mortality, readmissions or transfers to hospital, patient and caregiver satisfaction, place of residence at follow-up, length of stay, and cost | Moderate | |
Systematic review and meta-analysis Quantitative | Adult patients | Hospital at home schemes | Mortality and readmission | Moderate | |
Systematic review Quantitative | Patients aged 18 years and over | Hospital at home care | Mortality, re-admissions, costs, patient satisfaction, and carer satisfaction | Low |
Fig. 2Presentation of results about indicators of HBH model
Frequency and direction of reported indicators of HBH according to the NCPF
| Subsystems, dimensions, and indicators from the NCPF | No. of systematic reviews and meta-analyses | ||
|---|---|---|---|
| Positive indicators of HBH | Negative indicators of HBH | Neutral indicators of HBH | |
| Cost of resources | 9 | - | 5 |
| Use of hospital beds* | 1 | - | - |
| New emergency consultations* | 2 | - | - |
| Use of healthcare services* | 1 | ‑ | - |
| Cost per case-mix or patient-day | 1 | - | - |
| Problem and symptom management | 3 | - | 1 |
| Continuity (reactivity, timeliness, coordination) | 1 | - | - |
| Patient/family involvement (self-care/information/education) | 1 | - | 1 |
| 2 | 1 | - | |
| Medication management: errors and complications | - | 1 | 2 |
| Pulmonary infections | - | 1 | - |
| Pressure ulcers/skin integrity | - | 1 | - |
| Urinary complications | 1 | - | - |
| Bowel complications* | 1 | - | |
| Intravenous infections | - | 2 | - |
| Symptom management (e.g., pain, nausea, dyspnea, fever) | 3 | - | - |
| Comfort and quality of life (taken broadly) | 5 | - | 3 |
| Physical functional capacity | - | 1 | - |
| Cognitive and psychosocial functional capacity | 5 | - | 1 |
| Functional capacity | 1 | - | 4 |
| Nutritional status | 2 | - | - |
| Patient satisfaction/complaints | 11 | 1 | 2 |
| Satisfaction of caregivers and complaints* | 4 | 2 | 3 |
| Hospital mortality | 5 | - | 7 |
| Readmissions | 4 | - | 7 |
| Length of stay | 6 | 1 | 2 |
| Survival time* | - | - | 1 |
*New HBH indicator identified in the systematic reviews and meta-analyses and integrated to the NCPF
Frequency of factors identified as facilitators or barriers to the implementation of the HBH model
| Factor | No. of systematic reviews and meta-analyses | Example of quotes | |
|---|---|---|---|
| No. of barriers | No. of facilitators | ||
| 1.1 Characteristics of innovation | 2 | 3 | Individual’s home situation, social support networks [ |
| 1.2 Patient empowerment | - | 3 | Patient and carer education for the recognition and management of acute exacerbation of chronic obstructive pulmonary disease [ |
| 2.1 Confidence in HBH developer or vendor | 1 | - | Patients refused HBH due to lack of confidence and were admitted to hospital [ |
| 2.2 Autonomy | - | 1 | Differences were reported for patients’ preferred place of care, with each group of patients preferring care at home [ |
| 2.3 Sociodemographic characteristics | - | 1 | Strong evidence that patients aged 75 and over may be safely included in early supported discharge (ESD) and hospital at home (HAH) schemes. Most patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease are elderly [ |
| 3.1 Patient and health professional interaction | 1 | - | Miscommunication in teaching the parents [ |
| 4.1.1.1 Practice size | - | 1 | Nursing care available for 24 h if required [ |
| 4.1.1.2 Workforce issues (shortage, retention) | 1 | - | Lack of access to 24-h care [ |
| 4.1.2.1 Work flexibility | - | 1 | Evening and night cover was provided by a direct line to medical chest unit or provided by district nurses [ |
| 4.1.3.1 Skill mix | - | 11 | The service was co-ordinated by a nurse [ |
| 4.1.3.2 Multidisciplinary collaboration | - | 10 | Nurse and medical team (including a physician) [53. Specialist and dedicated nurses, specialist physicians, social worker, dietitian, physiotherapist, occupational therapist (OT), speech therapist, and volunteers [ |
| 4.1.4.1 Material resources (access to information and communication technology) | - | 3 | Telephone support [ Lab values and ECGs done at home, radiographs and echocardiograms at hospital [ |
| 4.1.4.2 Human resources (information technology (IT) support, other) | 1 | 1 | Staff reported that the service was better staffed than usual after care services [ |
Medline (OVID)
| Search | Query | Results |
|---|---|---|
| (hospital adj2 home).tw. | 3707 | |
| home based versus hospital based.tw. | 14 | |
| home hospitalization.tw. | 133 | |
| exp Home Care Services/ | 44,262 | |
| exp Hospitalization/ | 205,749 | |
| 4 and 5 | 4826 | |
| 1 or 2 or 3 or 6 | 8068 | |
| Meta-Analysis as Topic/ | 16,136 | |
| meta analy$.tw. | 125,472 | |
| metaanaly$.tw. | 1822 | |
| Meta-Analysis/ | 87,336 | |
| (systematic adj (review$1 or overview$1)).tw. | 119,387 | |
| exp Review Literature as Topic/ | 9820 | |
| or/8-13 | 227,170 | |
| cochrane.ab. | 60,038 | |
| embase.ab. | 63,584 | |
| (psychlit or psyclit).ab. | 909 | |
| (psychinfo or psycinfo).ab. | 22,332 | |
| (cinahl or cinhal).ab. | 20,527 | |
| science citation index.ab. | 2751 | |
| bids.ab. | 451 | |
| cancerlit.ab. | 623 | |
| or/15-22 | 104,043 | |
| reference list$.ab. | 15,147 | |
| bibliograph$.ab. | 15,647 | |
| hand-search$.ab. | 5844 | |
| relevant journals.ab. | 1042 | |
| manual search$.ab. | 3685 | |
| or/24-28 | 37,062 | |
| selection criteria.ab. | 26,761 | |
| data extraction.ab. | 16,097 | |
| 30 or 31 | 40,796 | |
| Review/ | 2,369,814 | |
| 32 and 33 | 27,208 | |
| Comment/ | 713,540 | |
| Letter/ | 983,939 | |
| Editorial/ | 455,744 | |
| animal/ | 6,190,908 | |
| human/ | 17,017,485 | |
| 38 not (38 and 39) | 4,414,780 | |
| or/35-37,40 | 5,976,817 | |
| 14 or 23 or 29 or 34 | 273,439 | |
| 42 not 41 | 259,332 | |
| 7 and 43 |
CINAHL Plus with Full Text
| Search | Query | Results |
|---|---|---|
| S11 | S5 AND S10 | |
| S10 | S6 OR S7 OR S8 OR S9 | 126,202 |
| S9 | systematic N2 (review or overview) | 92,36 |
| S8 | (MH “Literature Review+”) | 62,327 |
| S7 | Meta analys* OR Metaanaly* | 56,065 |
| S6 | (MH “Meta Analysis”) | 31,89 |
| S5 | S1 OR S2 OR S3 OR S4 | 7688 |
| S4 | (MH “Home Health Care”) AND (MH “Hospitalization”) | 590 |
| S3 | TI Home hospitalization OR AB Home hospitalization | 3477 |
| S2 | TI Home-based versus hospital-based OR AB Home-based versus hospital-based | 24 |
| S1 | TI hospital N2 home OR AB hospital N2 home | 4222 |
Embase
| Search | Query | Results |
|---|---|---|
| # 32 OR #39 | ||
| #33 OR #34 OR #35 OR #38 | 9305 | |
| #36 AND #37 | 4243 | |
| ‘hospitalization’/de | 302,681 | |
| ‘home care’/exp | 66,443 | |
| ‘home-based versus hospital based’:ab,ti | 18 | |
| ‘home hospitalization’:ab,ti | 199 | |
| (‘hospital’ NEAR/2 ‘home’):ab,ti | 5258 | |
| #31 NOT #30 | 372,637 | |
| #4 OR #13 OR #19 OR #24 | 387,258 | |
| #25 OR #26 OR #29 | 2,985,597 | |
| #27 NOT (59 AND #28) | 1,394,722 | |
| ‘human’/de | 19,205,255 | |
| ‘animal’/de | 1,829,542 | |
| ‘letter’:it OR ‘letter’/de | 1,013,470 | |
| ‘editorial’:it OR ‘editorial’/de | 602,895 | |
| #22 AND #23 | 24,469 | |
| ‘review’/de OR review:it | 2,445,565 | |
| #20 OR #21 | 48,611 | |
| ‘selection criteria’:ab | 31,177 | |
| ‘data extraction’:ab | 19,337 | |
| #14 Or #15 OR #16 OR #17 OR #18 | 42,960 | |
| ‘relevant journals’:ab | 1210 | |
| ‘manual search*’:ab | 4282 | |
| ‘hand-search*’:ab | 6862 | |
| ‘bibliograph*’:ab | 19,517 | |
| ‘reference lists’:ab | 15,852 | |
| #5 OR #6 OR #7 OR #8 OR #9 Or #10 OR #11 OR #12 | 123,233 | |
| bids:ab | 564 | |
| ‘science citation index’:ab | 3113 | |
| cinahl:ab OR cinalh:ab | 22,329 | |
| psychinfo:ab OR psycinfo:ab | 19,854 | |
| psychlit:ab OR psyclit:ab | 977 | |
| embase:ab | 78,585 | |
| cochrane:ab | 76,068 | |
| cancerlit:ab | 708 | |
| #1 OR #2 OR #3 | 340,912 | |
| (systematic NEAR/1 (review* OR overview*)):ab,ti | 143,580 | |
| ((meta NEAR/1 analy*):ti,ab) OR metaanalys*:ti,ab | 162,940 | |
| ‘systematic review’/de OR ‘meta analysis’/exp OR ‘meta analysis (topic)’/de | 272,499 |
Cochrane
| Search | Query | Results |
|---|---|---|
| hospital near/2 home:ti,ab,kw | 1004 | |
| home hospitalization:ti,ab,kw | 1880 | |
| Home-based versus hospital-based :ti,ab,kw | 60 | |
| #1 or #2 or #3 | ||
| Cochrane Database of Systematic Reviews (CDSR) | ||
| Database of Abstracts of Reviews of Effects (DARE) |
Preferred Reporting Items for Systematic review and Meta-Analysis extension for Network Meta-Analyses (PRISMA-NMA) checklist [31]
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review incorporating a network meta-analysis (or related form of meta-analysis). | 1 |
| Structured summary | 2 | Provide a structured summary including, as applicable: Background: main objectives. Methods: data sources; study eligibility criteria, participants, and interventions; study appraisal; and synthesis methods, such as network meta-analysis. Results: number of studies and participants identified; summary estimates with corresponding confidence/credible intervals; treatment rankings may also be discussed. Authors may choose to summarize pairwise comparisons against a chosen treatment included in their analyses for brevity. Discussion/conclusions: limitations; conclusions and implications of findings. Other: primary source of funding; systematic review registration number with registry name. | 2,3 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known, including mention of why a network meta-analysis has been conducted. | 3, 4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 5 |
| Protocol and registration | 5 | Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number. | 6 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. Clearly describe eligible treatments included in the treatment network and note whether any have been clustered or merged into the same node (with justification). | 6, 7 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 54 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 7 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6 |
| Geometry of the network | S1 | Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers. | 8 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | This is not applicable |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses. | This is not applicable |
| Planned methods of analysis | 14 | Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: handling of multigroup trial, selection of variance structure, selection of prior distributions in Bayesian analyses, and assessment of model fit. | This is not applicable |
| Assessment of inconsistency | S2 | Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found. | This is not applicable |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | This is not applicable |
| Additional analyses | 16 | Describe methods of additional analyses if done, indicating which were prespecified. This may include, but not be limited to, the following: sensitivity or subgroup analyses; meta-regression analyses; alternative formulations of the treatment network, and use of alternative prior distributions for Bayesian analyses (if applicable). | This is not applicable |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 9 |
| Provide a network graph of the included studies to enable visualization of the geometry of the treatment network. | |||
| Presentation of network structure | S3 | Provide a network graph of the included studies to enable visualization of the geometry of the treatment network. | 67 |
| Summary of network geometry | S4 | Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure. | 11, 76 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 11, 76 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment. | This is not applicable |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (1) simple summary data for each intervention group, and (2) effect estimates and confidence intervals. Modified approaches may be needed to deal with information from larger networks. | 9–11, 76 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence/credible intervals. In larger networks, authors may focus on comparisons versus a particular comparator (e.g., placebo or standard care), with full findings presented in an appendix. League tables and forest plots may be considered to summarize pairwise comparisons. If additional summary measures were explored (such as treatment rankings), these should also be presented. | 15-35 |
| Exploration for inconsistency | S5 | Describe results from investigations of inconsistency. This may include such information as measures of model fit to compare consistency and inconsistency models, | 39–41 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies for the evidence base being studied. | This is not applicable |
| Results of additional analyses | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, alternative network geometries studied, and alternative choice of prior distributions for Bayesian analyses). | This is not applicable |
| Summary of evidence | 24 | Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, researchers, and policymakers). | 36-39 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). Comment on the validity of the assumptions, such as transitivity and consistency. Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons). | 40–41 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence and implications for future research. | 41–42 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network. | 43 |
Primary studies of HBH included in systematic reviews and meta-analyses
| Primary studies | Systematic reviews and meta-analyses | Total | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | ||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | x | 5 | |||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | 4 | ||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | 4 | ||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | x | 4 | ||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | 4 | ||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | x | x | 6 | ||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | x | 5 | |||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | x | x | 6 | ||||||||||
| x | x | x | x | x | x | 6 | ||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | x | x | x | 6 | ||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | x | 4 | ||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | x | 2 | ||||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | x | 3 | |||||||||||||
| x | x | 2 | ||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | 1 | |||||||||||||||
| x | x | x | 3 | |||||||||||||
| x | 1 | |||||||||||||||
Excluded articles
| Justification | References of excluded articles |
|---|---|
| Ram FSF, Wedzicha JA, Wright JJ, Greenstone M. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD003573. DOI: 10.1002/14651858.CD003573. Update [ | |
Ram FSF, Wedzicha JA, Wright JJ, Greenstone M, Lasserson TJ. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database System Rev 2009 (4). 20 OCT 2003. DOI: 10.1002/14651858.CD003573 Update [ | |
| Conley J, O’Brien CW, Leff BA, et al. Alternative strategies to inpatient hospitalization for acute medical conditions: a systematic review. JAMA Intern Med 2016;176:1693–702.doi:10.1001/jamainternmed.2016.5974. Update [ | |
Shepperd S, Iliffe S. Hospital at home versus in-patient hospital care. Cochrane database of systematic reviews (online) 2001; null(3): CD000356. Update [ | |
| Shepperd S, Iliffe S. Cochrane reviews. Hospital at home versus in-patient hospital care. Nursing Times. 2001;97(38):37. Update [ | |
| Parkes J, Shepperd S. Cochrane reviews. Discharge planning from hospital to home. Nursing Times. 2001;97(37):42. Update [ | |
Shepperd S, Iliffe S. Hospital at home versus in-patient hospital care. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD000356. DOI: 10.1002/14651858.CD000356.pub2. Update [ | |
Langhorne P, Dennis M, Kalra L, Shepperd S, Wade D, Wolfe CDA. Services for helping acute stroke patients avoid hospital admission. Cochrane Database of Systematic Reviews 1999, Issue 3. Art. No.: CD000444. DOI: 10.1002/14651858.CD000444. Update [ | |
| Without author. ‘Hospital at home’ schemes are as safe as inpatient care for people with exacerbated chronic obstructive pulmonary disease (COPD). Evidence-Based Healthcare and Public Health. 2005;9(1):46-7. | |
| Inpatient and hospital-at-home care: the same outcomes? Nursing Times, 104 (48), 29; 2008. | |
| Grad R. Review: hospital-at-home care for early discharge or admission avoidance does not improve health outcomes. ACP J Club. 2002 Jul-Aug;137:23. | |
| Jacobs MB. Review: hospital-at-home care does not increase mortality or readmission rates in acute exacerbations of COPD. ACP Journal Club. 2004;140(3):59. | |
| Reishtein JL. Review: hospital at home is as effective as inpatient care for mortality and hospital readmissions in patients with acute exacerbations of chronic obstructive pulmonary disease. Evidence Based Nursing. 2005;8(1):23. | |
| Dickson HG. A meta-analysis of “hospital in the home”. Comment. The Medical journal of Australia. 2013;198(4):195. | |
| Mas MT, Santaeugènia S. Hospital-at-home in older patients: a scoping review on opportunities of developing comprehensive geriatric assessment based services. Revista Espanola de Geriatria y Gerontologia. 2015;50(1):26-34. | |
| Messecar D. Review: admission-avoidance hospital-at-home decreases mortality at 6 months but does not differ from inpatient care for readmission. Evidence Based Nursing. 2009;12(3):82. | |
| Mitre Cotta RM, Suárez-Varela MM, Llopis González A, Cotta Filho JS, Real ER, Días Ricós JA. Home hospitalization: background, current situation, and future prospects. Revista Panamericana de Salud Publica. 2001;10(1):45-55. | |
| Goossens LMA, Vemer P, Rutten-Van Mölken MPMH. A systematic review of hospital-at-home care: cost savings are overestimated. Value in Health. 2012;15(7):A301. | |
| Iliffe S, Shepperd S. What do we know about hospital at home? Lessons from international experience. Applied health economics and health policy. 2002;1(3):141-7. | |
| McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ontario Health Technology Assessment Series. 2012;12(10):1-65. | |
| Shepperd S, Cates C. Hospital at home in chronic obstructive pulmonary disease: is it a viable option? Cochrane Database of Systematic Reviews [Internet]. 2012; (5). Available from: | |
| Caplan GA. A meta-analysis of “hospital in the home”. The Medical journal of Australia. 2013;198(4):195-6. | |
| Shepperd S, Wee B, Straus SE. Hospital at home: home-based end of life care. Cochrane Database of Systematic Reviews. 2011(7):CD009231. | |
| Shepperd S, Doll H, Angus RM, Clarke MJ, Iliffe S, Kalra L, et al. Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data. CMAJ: Canadian Medical Association Journal. 2009;180(2):175-82. | |
| Conley J, O'Brien CW, Leff BA, Bolen S, Zulman D. Alternative strategies to inpatient hospitalization for acute medical conditions: a systematic review. JAMA Internal Medicine. 2016;176(11):1693-702. |
Characteristics of studies included in detail
| Author, year, country | Type of reviews or designs | No. of studies | Study country | Population | Intervention | Outcomes | AMSTAR |
|---|---|---|---|---|---|---|---|
Systematic review Mixed | 5 RCT* 2 nRCT* 7 single-arm prospective trials 2 qualitative studies 1 retrospective cohort study | European countries, mostly France and United Kingdom (UK) Other studies from: Belgium, Israel, Germany, Ireland, Spain, Switzerland, Sweden, Australia, Canada, and United States of America (USA) | Adult patients | Parenteral cancer drug administration in hospital at home care | Quality of life, patient’s satisfaction, safety, and costs | Moderate quality review | |
Systematic review Qualitative | 21 RCTs, among which 4 RCTs about HBH | Spain | Not specified | Interventions supporting continuity of care, including HBH | Number of readmissions, mortality, or improvement in functional capacity | Moderate quality review | |
Systematic review and meta-analysis Quantitative | 32 RCTs | A majority of studies are from the UK, Australia, and Norway. Other studies from: Canada, Chile, Italy, New Zealand, Spain, Sweden, Thailand, The Netherlands, and Turkey | Patients aged 18 years and over, acute episode of care | Early discharge hospital at home | Effectiveness and cost of the intervention | High quality review | |
Systematic review Qualitative | 10 RCTs 9 nRCTs Among them 11 studies (6 RCTs and 5 nRCTs) about HBH | European countries, principally UK | Patients aged over 65 years at risk of an unplanned admission | Any community-based intervention offered as an alternative to admission to an acute hospital | Reduction in secondary care use, patient-related outcomes, safety, and costs | Moderate quality review | |
Systematic review and meta-analysis Quantitative | 3 RCTs 1 nRCT | Norway, UK, and USA | People aged 18 years and older, who would otherwise require hospital or hospice inpatient end-of-life care | Home-based end-of-life care | Place of death, unplanned/precipitous admission to or discharge from hospital, control of symptoms, delay in care from point of referral to intervention, participant health outcomes, family- or caregiver-reported symptoms, family or caregiver unable to continue caring, participant’s preferred place of death, health service use, including system and caregiver costs | High quality review | |
Systematic review and meta-analysis Quantitative | 16 RCTs | Australia, Italy, New Zealand, Romania, Spain, UK, and USA | Patients aged 18 years and over (older patients = 65 years and older). Patients to be clinically stable and not requiring specialist diagnostic investigation or emergency interventions | Hospital at home | Mortality, transfer (or readmission) to hospital, functional status, quality of life or self-reported health status, cognitive function, depression, clinical outcomes, place of residence at follow-up (living in a residential setting), patient satisfaction, caregiver outcomes, health professionals’ views, length of stay in hospital and hospital at home, cost, use of other health services and informal care | High quality review | |
Systematic review and meta-analysis Quantitative | 7 RCTs | UK, Netherlands, Australia, Italy | Patients with acute exacerbation of chronic obstructive pulmonary disease | Early supported discharge (ESD) and hospital at home (HAH) | Structure of ESD/HAH schemes, number of patients experiencing one or more readmissions, mortality and cost, comparing cost across different countries and healthcare structures | Moderate quality review | |
Systematic review and meta-analysis Quantitative | 3 RCTs 3 nRCTs among which 5 studies (3 RCTs and 2 nRCTs) are about HBH | Spain, Italy, Sweden | Patients who required hospitalization for decompensated heart failure | Substitutive care models | Mortality, hospital readmissions, other clinical, patient-centered, and cost outcomes | High quality review | |
Systematic review and meta-analysis Quantitative | 61 RCTs among which 26 RCTs about HBH | Countries are not explicitly mentioned | Patients aged > 16 years | Hospital at home care models regardless of temporal-, team- and disease-specific frameworks | Mortality, readmission rates, patient and carer satisfaction, and costs | Moderate quality review | |
Systematic review and meta-analysis Quantitative | 8 RCTs | Australia, Denmark, Italy, Spain, UK | Patients with a diagnosis of COPD with an acute exacerbation | Hospital at home care | Readmission rate, mortality, costs and days of care provision | High quality review | |
Systematic review Quantitative | 1 RCT 1 control group 3 studies had no true control group | USA, Canada, and Italy | Children and adolescents aged 0–18 years with a cancer diagnosis | Medical treatments relevant for childhood cancer provided by hospital- or community-based healthcare professionals who take an active part in the care in the patient’s own home as an alternative to a hospital admission | Children’s physical health, adverse events, parental and child satisfaction, QOL of children and their parents, and costs of using hospital data, questionnaires, or satisfaction surveys | Low quality review | |
Systematic review and meta-analysis Quantitative | 26 RCTs | Countries are not explicitly mentioned | Patients aged 18 years and over (older patients = 65 years and older). People requiring long-term care needs were not included unless they required admission to hospital for an acute episode of care | Early discharge hospital at home | Mortality, readmissions, general and disease-specific health status, functional status, psychological well-being, clinical complications, patient satisfaction, carer satisfaction, carer burden, staff views, discharge destination from hospital at home, length of stay in hospital and hospital at home, cost | Moderate quality review | |
| Systematic Review and Meta-Analysis Quantitative | 10 RTCs | Australia, Italy, New Zealand and the UK | Patients aged 18 years and older entered the program directly from the community or from the emergency department | Hospital care at home | Mortality, readmissions or transfers to hospital, general and disease-specific health status, functional status, psychological well-being, clinical complications, patient and caregiver satisfaction, caregiver burden, staff perspectives, place of residence at followup, length of stay and cost | Moderate quality review | |
| Systematic review and meta-analysisQuantitative | 7 RTCs | Spain, Australia (not explicitly mentioned other countries included) | Adult patients attending an emergency department with an acute exacerbation within 72 h of presenting to the department and after an | Hospital at home schemes | Mortality and readmission | Moderate quality review | |
Systematic review Quantitative | 5 RCTs | UK, USA | Patients aged 18 years and over needing treatment during an acute episode of care | Hospital at home care | Mortality, clinical complications, re-admissions, costs, hospital days saved from the provision of hospital at home, discharge destination from hospital at home, functional status, psychological well-being, patient satisfaction, and carer satisfaction | Low quality review |
*Legend: Randomized controlled trial (RTC) and Non-randomized controlled trial (nRTC)
Strength of evidence of reported indicators of HBH model using GRADE [46].
| Effects | [ | [ | [ | [ |
|---|---|---|---|---|
| Moderate | - | Low | Moderate | |
| Moderate | - | Moderate | Moderate | |
| Low | - | Low | - | |
| Low | - | Low | - | |
| - | High | - | - | |
| - | Moderate | - | - | |
| Low | Low | Low | Low | |
| - | Low | - | - | |
| - | - | - | Very low | |
| Low | Low | Very low | Very low | |
| - | - | - | Very low |
Legend: GRADE Working Group grades of evidence: High certainty: further research is very unlikely to change our confidence in the estimate of effect. Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low certainty: we are very uncertain about the estimate